Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.10
Ask: 2.20
Change: 0.00 (0.00%)
Spread: 0.10 (4.762%)
Open: 2.15
High: 2.15
Low: 2.15
Prev. Close: 2.15
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of patient enrolment in Phase 3 study

10 Oct 2017 07:00

RNS Number : 1132T
Shield Therapeutics PLC
10 October 2017
 

 

Shield Therapeutics plc

("Shield" or the "Group")

 

Completion of patient enrolment in pivotal AEGIS-CKD Phase 3 study 

 

Top line data anticipated early in the first quarter of 2018

 

London, UK, 10 October 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces the completion of enrollment of the pivotal Phase 3 AEGIS-CKD study of its European-marketed product, Feraccru®. Top-line data, based on the 16-week primary endpoint, is anticipated early in the first quarter of 2018. Subjects were enrolled in 30 renal centres across the USA.

 

A positive outcome from this study will enable initiation of the regulatory filing with the US FDA that could lead to the commercialisation of Feraccru in the US and increase the target population for Feraccru from c. 330,000 Inflammatory Bowel Disease (IBD) patients with Iron Deficiency Anaemia (IDA) in Europe to c. 2.6m patients with IDA related to both IBD and CKD in Europe and the USA.

 

The study is evaluating Feraccru (ferric maltol, 30mg bd) compared to placebo in the treatment of IDA in patients with non-dialysis Chronic Kidney Disease (CKD). Feraccru is currently approved in Europe for the treatment of IDA in adults with IBD. Shield recently filed for approval of an expanded label for Feraccru in Europe.

 

Dr Mark Sampson, Chief Medical Officer of Shield Therapeutics, commented: "We are pleased to reach this important recruitment milestone. Many CKD patients struggle to tolerate currently available oral iron preparations, resulting in poor control of their IDA. We look forward to the data early in the first quarter of 2018 and to taking the next steps to make Feraccru available to as many patients as quickly as possible. I would like to thank the patients for their willingness to participate, as well as the clinicians and colleagues who have worked so diligently on this programme."

 

- Ends -

 

For further information please contact:

 

Shield Therapeutics plc +44 (0)207 186 8500

Dr Mark Sampson, Chief Medical Officer

Carl Sterritt, Chief Executive Officer

Karl Keegan, Chief Financial Officer

 

Nominated Advisor and Joint Broker +44 (0)203 100 2222

Liberum Capital Limited

Christopher Britton/Steve Pearce

 

Joint Broker +44 (0)207 418 8900

Peel Hunt LLP

James Steel/Dr Christopher Golden

 

Financial PR Advisor +44 (0)203 709 5700

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

 

US Investor Relations +1 (212) 867 1762

Lazar Partners

Fern Lazar/ David Carey

 

 

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.

 

About Feraccru®

Feraccru® is Shield's lead product and is a novel therapy for the treatment of IDA. Feraccru® received marketing authorisation across Europe in February 2016 for the treatment of IDA in adult patients with IBD and is in the early stages of commercialisation in European markets. The Group is currently completing a pivotal Phase 3 clinical trial of Feraccru® in IDA patients with pre-dialysis CKD and expects to announce results of this study early in the first quarter of 2018. A positive result is expected to facilitate the filing of an NDA for Feraccru® in the US as well as significantly broader commercialisation in Europe and beyond.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESMMMGGKLDGNZM
Date   Source Headline
18th Feb 20222:00 pmRNSPrice Monitoring Extension
17th Feb 20229:05 amRNSSecond Price Monitoring Extn
17th Feb 20229:00 amRNSPrice Monitoring Extension
17th Feb 20227:00 amRNSFull Year Trading Update
4th Feb 20227:00 amRNSKOL Investor Event on Iron Deficiency
7th Jan 20227:00 amRNSInvestor Presentation
5th Jan 20227:00 amRNSLicence Agreement in Canada for Accrufer®
30th Dec 20219:06 amRNSSecond Price Monitoring Extn
30th Dec 20219:00 amRNSPrice Monitoring Extension
29th Dec 202111:05 amRNSSecond Price Monitoring Extn
29th Dec 202111:00 amRNSPrice Monitoring Extension
16th Dec 202111:05 amRNSSecond Price Monitoring Extn
16th Dec 202111:00 amRNSPrice Monitoring Extension
16th Dec 20217:00 amRNSPatient Access Expands for Accrufer®
7th Oct 20219:45 amEQSHardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research
30th Sep 20215:30 pmRNSBlock Listing 6 Monthly Return
27th Sep 20217:00 amRNSJose A. Menoyo Appointed as Chief Medical Officer
21st Sep 20217:00 amRNSInvestor presentation
23rd Aug 20217:00 amRNSPDMR Transaction Notification
20th Aug 202111:08 amEQSHardman & Co Research: Shield Therapeutics (STX) - Focused on US market penetration
17th Aug 20217:00 amRNSHalf-year Report
12th Aug 20217:25 amEQSHardman & Co Video Event | Shield Therapeutics plc - Investor Forum
12th Aug 20217:00 amRNSLicence agreement secured in Republic of Korea
11th Aug 20217:00 amRNSNotice of Results
9th Aug 20217:00 amRNSAEGIS-CKD study results published in AJKD
4th Aug 20214:41 pmRNSSecond Price Monitoring Extn
4th Aug 20214:35 pmRNSPrice Monitoring Extension
4th Aug 20212:05 pmRNSSecond Price Monitoring Extn
4th Aug 20212:00 pmRNSPrice Monitoring Extension
24th Jun 20217:00 amRNSUS launch of Accrufer® confirmed for July 1, 2021
23rd Jun 20214:40 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:35 pmRNSPrice Monitoring Extension
21st Jun 20211:35 pmRNSInvestor presentation
18th Jun 20217:00 amRNSDirectorate Change
17th Jun 20212:30 pmRNSResults of 2021 Annual General Meeting
15th Jun 20216:15 pmRNSGrant of share options to the CEO
28th May 20217:00 amRNSAppointment of new Chief Executive Officer
28th May 20217:00 amRNSTotal Voting Rights
26th May 202110:35 amEQSHardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule
21st May 20217:00 amRNSUS update
18th May 20217:00 amRNSAEGIS-H2H study results published in IBD
17th May 20217:00 amRNSCommencement of trading on the OTCQX Best Market
13th May 20213:00 pmRNS2020 Annual Report and 2021 AGM Notice
10th May 20217:00 amRNSAppointment of Two Non-Executive Directors
6th May 20211:44 pmRNSTotal Voting Rights Update
29th Apr 20217:00 amRNSPreliminary Results
22nd Apr 20217:00 amRNSNotice of Results
7th Apr 20219:33 amRNSHolding(s) in Company
7th Apr 20219:31 amRNSHolding(s) in Company
6th Apr 202111:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.